Ceregene

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

... analyses of the therapeutic effects of CERE-120. ceregene gratefully acknowledges the financial support rece..., let alone cure Parkinson's disease. About ceregene Ceregene, Inc. is a San Diego-based biotechnol...ig's disease) and ocular disorders, respectively. ceregene was launched in January 2001. The company's inves...

Global Growth Factors (Blood and Tissue) Market to Reach $52.1 Billion by 2012, According to New Report by Global Industry Analysts

...actors (Blood and Tissue) market include Amgen Inc, BioMimetic Therapeutics Inc, Biopharm GmbH, Bolder Biotechnology Inc, Alseres Pharmaceuticals Inc, ceregene Inc, FibroGen Inc, FzioMed Inc, GeneMedix Plc, Insmed Inc, Johnson & Johnson, Janssen-Ortho Inc, Lonza Group, Maxygen Inc, Merck Serono Internatio...

Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health

...dy was too small to make a definitive statement about treatment efficacy. ceregene anticipates initiating the Phase 2 study, which is expected to enroll 50 pa...elopment for ALS (Lou Gehrig's disease) and ocular disorders, respectively. ceregene was launched in January 2001. The company's investors include Alta Partners...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

...elated to the consolidation of our former tracking stocks. (4) Includes a charge of $(25,000)K for an upfront milestone payment paid to ceregene Inc. in June 2007 for the development and commercialization of certain gene therapy products. (5) Includes charges for the purchase of in-pro...

Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease

...120's development as well as in the development of ceregene as an emerging biotechnology company," stated Jeff... currently no cure for Parkinson's disease. About ceregene Ceregene, Inc. is a San Diego-based biotechnology...rig's disease) and ocular disorders, respectively. ceregene was launched in January 2001 and is a former subsi...

Ceregene in Medical Technology

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

...study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. ceregene was launched in January 2001 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, MPM Cap...

Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

...d in this study can be found through a link on the ceregene web site: ceregene at this particular juncture in the company's histo... novel neurological products will be invaluable to ceregene as our programs continue to mature," stated Dr. Ba...ams as a key member of our executive team." About ceregene Ceregene, Inc. is a San Diego-based biotechnology...